Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex vs Neostigmine for Reversal of Neuromuscular Blockade
NCT00451217Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2005
- Primary completion
- Mar 2006
- Modality
- Biodegradable Polymers, Small Molecules
01
Overview
A Phase 3 trial of Sugammadex in neuromuscular blockade (NMB), sponsored by Merck & Co.. Started Nov 2005; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT00451217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00451217.